Therapeutic potential of Triptolide in inhibiting breast cancer-induced bone destruction – PTHrP as a therapeutic target
This study demonstrates that Triptolide effectively inhibits breast cancer-induced osteolytic bone metastasis by suppressing key osteoclastogenic signaling pathways and modulating the tumor-bone microenvironment. We provide the first evidence of a direct interaction between TP and PTHrP, suggesting a novel mechanism through which TP may disrupt PTHrP-mediated osteoclast activation. These findings position TP as a promising alternative to current anti-resorptive therapies for managing breast cancer-associated bone metastases.
Authors
- Xiangyu Hu (ORCID: https://orcid.org/0000-0002-1599-5667)
- Gang Wu (ORCID: https://orcid.org/0000-0002-4764-8272)
- Di Wu (ORCID: https://orcid.org/0000-0002-2739-1625)
- Minghan Li (ORCID: https://orcid.org/0009-0005-4035-6532)
- Zidong Wang (ORCID: https://orcid.org/0009-0002-3813-0110)
- Huang Zining
- Zhou Chunshi
Institutions
- Hubei University of Chinese Medicine (CN)
- Hubei Provincial Hospital of Traditional Chinese Medicine (CN)
- Hubei University (CN)
- Wuhan Sports University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.3389/fphar.2025.1512631
- Citations
- 1
- Primary Topic
- Natural Compounds in Disease Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.38
Funders
- Natural Science Foundation of Hubei Province